Foundation seeking to defeat aging proposes four US therapy approval reforms, three requiring no new legislation
Foundation seeking to defeat aging proposes four US therapy approval reforms, three requiring no new legislation
On November 17, Vitalism Foundation co-founder Adam Gries and lawyer Ian Huyett presented their paper “Bio-Tetrarchy”, which compares pathways for authorizing therapies in the US, China, Japan, and Australia. Huyett helped draft New Hampshire’s right-to-try law, which provides access to unapproved therapies.
The authors describe a single scalable route to market for a drug in the US: a company pays for multiple phases of clinical trials, and the FDA decides whether those trials can begin and whether the therapy can reach patients. “A therapy developed for one person cannot follow the same development economics as a drug sold to millions,” Gries wrote. After the first personalized gene therapy for an infant, KJ Muldoon, then-FDA leaders Marty Makary and Vinay Prasad acknowledged that the rules for such therapies were “burdensome and unnecessarily demanding, offer no clear protection for patients, and stifle innovation.”
The authors trace the problem to legal definitions: almost anything used to treat a patient qualifies as a “drug” or “biologic,” putting it on the same regulatory path. In 2014, an appeals court ruled that a patient’s own stem cells, treated with an antibiotic, constituted a drug, although the clinic regarded the procedure as the practice of medicine. IVF also fits these definitions, but the FDA treats it as the practice of medicine, governed by medical licensing and state law. The authors attribute such exceptions, including peptides compounded by pharmacies without approval, to chance, political advantage, or lobbying. They argue that these exceptions show that access to therapies can be regulated differently.
In Australia, developers generally need only ethics committee approval and notification of the regulator: according to the US Department of Health and Human Services, a trial begins less than 70 days after the protocol is submitted. In China, hospitals can authorize some trials themselves: in 2016, a hospital committee approved the world’s first human CRISPR gene-editing trial on July 6, and the first patient was treated in late October. The first US CRISPR trial took more than two years to secure approval.
The authors discuss the death of six-year-old Mei (a pseudonym). The ethics committee at Shanghai’s Xinhua Hospital authorized the gene therapy; a week after administration, an immune reaction to the virus delivering the therapy caused kidney failure. Science noted that the trial had proceeded without approval from the national regulator. The authors counter that the journal leaves out the “invisible graveyard” of patients who die because therapies are delayed. On November 13, Shanghai authorities announced the findings of an investigation: the committee had approved the trial before receiving the safety materials it had requested from the developers, and the consent form had not listed death as a risk.
The first reform would be a written commitment by federal agencies to refrain from enforcement against those who comply in good faith with robust state right-to-try laws, such as Montana’s, where a private board reviews each treatment protocol in advance. The model is the 2013 Cole memorandum, which instructed US prosecutors to rely largely on states with robust marijuana regulation. The second would classify some personalized biologics as the practice of medicine, as IVF is treated: individualized gene therapy would become “gene surgery” overseen by ethics committees. The third would establish a “green channel” similar to China’s, but initiated by the regulator, allowing therapies to be authorized on the basis of real-world evidence and surrogate measures of benefit. It would begin with a policy of non-enforcement, as with pharmacy-compounded peptides. The fourth would create a single federal appeals court for drugs and biologics, staffed by specialist judges, as in patent disputes; this reform would require congressional action.
- https://vitalismfoundation.org/research/bio-tetrarchy
- https://x.com/adamgries/status/2122786296255168702
- https://t.me/UkhvatNews/345
- https://www.biopharmadive.com/news/fda-plausible-mechanism-pathway-n-of-1-crispr/805235/
- https://www.hhs.gov/sites/default/files/operation-trialblazer.pdf
- http://www.xinhuanet.com/english/2016-08/02/c_135558101.htm
- https://www.nature.com/articles/nature.2016.20988
- https://www.pennmedicine.org/news/crispr-edited-immune-cells-can-survive-and-thrive-after-infusion-into-cancer-patients
- https://t.me/UkhvatNews/2564
- https://www.nature.com/articles/d41586-026-03752-2
- https://t.me/UkhvatNews/4838